The study drug is designed to reverse fibrosis (scarring) in the organs, which can lead to various heart, kidney, and lung diseases.
The drug will be taken in the form of an oral capsule and mimics the role of a naturally occurring peptide hormone called Vasoactive Intestinal Peptide (VIP). VIP plays different roles in the body and lack of this hormone in organs like the heart and kidneys can result in the development of scar tissue (fibrosis). Ultimately, this can lead to loss of heart or kidney function.
The study drug is designed to reverse fibrotic damage to organs, and it may prove to be a new treatment for heart and kidney failure. This means that there could be reduced need for dialysis and/or transplantation in patients with kidney failure and cardiac transplantation in patients with severe heart failure could be prevented.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!